thymosin beta-4 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
November 13, 2009: Germany, Eurozone Germany's growth of 0.7% in the third quarter helped lead the Eurozone out of the recession after providing overall growth of 0.4% in the same period, with the whole European Union growing 0.2%.
== Research == Chutia's research focuses on biomedicine, material science and biotechnology. Her research has led to the development of a highly durable and degradable wound suturing material from Muga Silk.
== Bayesian inference of phylogeny background and bases == Bayesian inference refers to a probabilistic method developed by Reverend Thomas Bayes based on Bayes' theorem. Published posthumously in 1763 it was the first expression of inverse probability and the basis of Bayesian inference. Independently, unaware of Bayes' work, Pierre-Simon Laplace developed Bayes' theorem in 1774. Bayesian inference or the inverse probability method was the standard approach in statistical thinking until the early 1900s before RA Fisher developed what's now known as the classical/frequentist/Fisherian inference. Computational difficulties and philosophical objections had prevented the widespread adoption of the Bayesian approach until the 1990s, when Markov Chain Monte Carlo (MCMC) algorithms revolutionized Bayesian computation. The Bayesian approach to phylogenetic reconstruction combines the prior probability of a tree P(A) with the likelihood of the data (B) to produce a posterior probability distribution on trees P(A|B). The posterior probability of a tree will be the probability that the tree is correct, given the prior, the data, and the correctness of the likelihood model. MCMC methods can be described in three steps: first using a stochastic mechanism a new state for the Markov chain is proposed. Secondly, the probability of this new state to be correct is calculated. Thirdly, a new random variable (0,1) is proposed. If this new value is less than the acceptance probability the new state is accepted and the state of the chain is updated.
in military personnel exposed to high radiation, (during accidents at nuclear reactors), or to combat the action of toxic substances (including organophosphate compounds), combat traumas, as well as to prevent acute respiratory infections and flu. They were also used to treat laser retinal lesions in experimental animals exposed to a combat laser. All other peptide preparations, (natural and synthetic) are at different stages of studying in patients with different diseases. Among the important advantages of all designed peptide preparations is that they lack any toxic, allergic or adverse effects, this has been proven both in experimental and clinical studies. The main objective of studies for the recent decade was fundamental research devoted to the role that small peptides play in the evolution and development of living matter. It was crucial for understanding the mechanism of the action of peptides and evidencing their safety and effectiveness, whilst designing new medicinal preparations, dietary supplements, cosmetics and veterinary preparations.
Sources: en.wikipedia.org
== Tissue distribution == Studies have detected FFAR2 protein and/or its messenger RNA (an indicator of FFAR2 protein expression) in the following cell types, cell lines, and tissues: 1) human and rodent enteroendocrine K cells, i.e., cells located in the epithelium of the small intestine; 2) human and rodent enteroendocrine L cells, i.e., cells located in the epithelium of the small intestine and colon; 3) human and rodent fat tissue and/or cultured fat cells; 4) cells in human and rodent pancreatic islets (these islets contain the beta cells and alpha cells that synthesize and secrete insulin and glucagon, respectively, into the blood); 5) cells in and/or derived from cells in the human or mouse spleen, lymph nodes, bone marrow, and blood (e.g., monocytes, lymphocytes, and neutrophils); 6) mouse and, based on indirect studies, human dendritic cells; 7) cells in or derived from cells in human and/or rodent kidneys, hearts, brains (e.g., hypothalamus), fetal membranes, and placentas; 8) cells in the taste buds' lingual papillae of human tongues; 9) mouse renal arteries, aortas, and iliac arteries; 10) various human cell lines including SW480, SW620, HT-29, and T84 colon cancer cells, NCI-H716 colon cancer cells that have a lymphoblast morphology, Caco-2 colorectal cancer cells, Hutu-80 duodenal cancer cells, SW872 liposarcoma cells, MDA-MB-231, MDA-MB-436, and MCF7 breast cancer cells, Huh7 and JHH-4 liver cancer cells, THP-1 acute myeloid leukemia cells, U937 acute promyelocytic leukemia cells, and K562 myelogenous leukemia cells; and 11) the various mouse and rat cell lines discussed below. FFAR2 is also expressed in a wide range of tissues in other animals such as cows, pigs, sheep, cats, and dogs.
A possible cause of incorrect urine test results is the presence of metabolites from other anabolic steroids, though modern urinalysis can usually determine the exact anabolic steroid used by analyzing the ratio of the two remaining nandrolone metabolites. As a result of the numerous overturned verdicts, the testing procedure was reviewed by UK Sport. In October 2007, three-time Olympic gold medalist for track and field Marion Jones admitted to use of the drug, and was sentenced to six months in jail for lying to a federal grand jury in 2000. Mass spectrometry is also used to detect small amounts of nandrolone in urine samples.
National DNA Day, 25 April 2006 Moderated Chat Transcript Archive Independent On Line article about Consciousness, 7 June 2006. Siegel RM, Callaway EM (December 2004). "Francis Crick's Legacy for Neuroscience: Between the α and the Ω". PLOS Biology. 2 (12): e419. doi:10.1371/journal.pbio.0020419. PMC 535570. PMID 17593891. 100 Scientists and Thinkers: James Watson and Francis Crick from Time magazine. Francis Crick: Nobel Prize 1962, Physiology or Medicine[link removed] First press stories on DNA but for the "second" DNA story in The New York Times, see: https://www.nytimes.com/packages/pdf/science/dna-article.pdf — for reproduction of the original text in June 1953. 50th anniversary series of articles -from The New York Times. Quotes Archived 7 February 2009 at the Wayback Machine of Robert Olby on exactly who may have discovered the structure of DNA. A celebration of Francis Crick's life in science. Francis Crick tells his life story at Web of Stories Bretscher M, Lawrence P (August 2004). "Francis Crick 1916–2004". Current Biology. 14 (16): R642–5. Bibcode:2004CBio...14.R642B. doi:10.1016/j.cub.2004.08.006. PMID 15324677. Article by Mark Steyn from The Atlantic in 2004. Review of Francis Crick: Hunter of Life's Secrets in Current Biology[link removed].
In castrated immature male rats, vosilasarm (at 10 mg/kg/day orally, the highest assessed dose) maximally stimulated prostate weight to 67%, seminal vesicle weight to 59%, and levator ani muscle weight to 117% compared to that induced with testosterone propionate 1 mg/kg/day. Moreover, when combined with testosterone propionate, vosilasarm partially antagonized the weight increases of the prostate gland and seminal vesicles, reducing them to 84% and 78% (both from 100%), respectively. Conversely however, the combination of testosterone propionate and vosilasarm was additive in terms of levator ani muscle weight stimulation, increasing it to 124%. Vosilasarm was found to stimulate muscle at a dose much lower than that required to stimulate the prostate. A dose of 0.3 mg/kg/day stimulated levator ani muscle weight to a similar extent relative to the levator ani weight in non-castrated controls. Conversely, a 33-fold higher dose of 10 mg/kg/day was required to stimulate prostate weight to a similar extent as that in non-castrated controls. Similarly, in gonadally intact immature rats, 0.3 mg/kg/day vosilasarm stimulated levator ani muscle weight to a similar extent as testosterone propionate 0.5 mg/kg/day, but a dose of 30 mg/kg/day (100-fold higher) was required to stimulate the prostate to a similar extent as testosterone propionate 0.5 mg/kg/day.
Valve had built the Puzzle Maker with the aid of educators, as to make it suitable for lesson plans as well as making it as easy for teachers to use to construct such plans. The Puzzle Maker is not limited to physics, but designed to be modular so that other fields, such as fundamental electronics or chemistry, could be included. The "Teach with Portals" initiative is built atop a stripped-down version of the Steam client, "Steam for Schools", that is designed to be used in schools, allowing instructors to control the installation of the games and lesson plans on the students' computers. These tools, as well as copies of Portal 2 and the Puzzle Maker, are being offered for free for all educators.
Sources: en.wikipedia.org
Feltenstein then took control of Thomas's care, even though he did not have admitting rights at St. Vincent's. The hospital's senior brain specialist, C. G. Gutierrez-Mahoney, was not called to examine Thomas until the afternoon of 6 November, some 36 hours after Thomas's admission. Caitlin, having flown from Britain, arrived at the hospital the following morning, by which time a tracheotomy had been performed. Her first words are reported to have been, "Is the bloody man dead yet?" Permitted to see Thomas for a short time, she returned, drunk, in the afternoon and made threats to John Brinnin. Feltenstein had her put into a straitjacket and committed to the River Crest Sanitarium. It is now believed that Thomas had been suffering from bronchitis, pneumonia, emphysema and asthma before his admission to St Vincent's. In their 2004 paper, Death by Neglect, D. N. Thomas and former GP Principal Simon Barton disclose that Thomas was found to have pneumonia when he was admitted to hospital in a coma. Doctors took three hours to restore his breathing, using artificial respiration and oxygen.
==== Harley ==== Ricky Legere fights a bully named Harley, to defend a French kid. The bully only taps out one time in the first round, and stands through the second one, leaving the bully with $9000.
CGRP is released from both the trigeminal ganglion (TG) and the trigeminal nucleus caudalis (TNC) in response to trigeminal nerve activation. CGRP activates receptors on meningeal blood vessels, causing dilation and changes in blood flow. CGRP also activates specialized nerve endings on the dura mater (nociceptors) that transmit pain signals from the dura to the central nervous system. Increased neuronal activity in the trigeminal pain pathway reaches higher cortical pain regions via the brainstem, midbrain and thalamus. Stimulation of the trigeminal nerve may result in release of neuropeptides such as CGRP, vasodilation of cerebral and dural blood vessels, neurogenic inflammation, and the transmission of pain signals via nerves in the meninges. Cerebrospinal fluid may also play a role in migraine by transferring signals released from the brain to overlying pain-sensitive meningeal tissues, including dura mater.
==== Scoring systems ==== To better understand how severe cachexia is in each person, doctors use scoring systems like the Cachexia Staging Score and Cachexia Score. The Cachexia Staging Score (CSS) looks at weight loss, muscle function, appetite loss, and lab test results to categorize people into four stages: non-cachexia, pre-cachexia, cachexia, and refractory cachexia. Those in more advanced stages have less muscle mass, more frequent age-related muscle loss, worse symptoms, poorer quality of life, as well as shorter survival periods.
== President of the Council of Ministers of Togo (2025–present) == In 2024, Togo's parliament approved changes to the constitution which converted the country's presidential system to a parliamentary one, stripping off most of the powers of the presidency and making it a ceremonial role and as well as lowering the presidential term from five years to four with re-election permitted just once. The role of the prime minister was renamed President of the Council of Ministers, with most of the powers previously associated with the president being transferred to the role, thus making the President of the Council of Ministers the most powerful person in the country with the most governing authority. The new form of government was known as the Fifth Republic of Togo. The new system took effect on 3 May 2025, where Gnassingbé was sworn in as President of the Council of Ministers, with Jean-Lucien Savi de Tové, a former opposition figure to Gnassingbé's father, being elected by the entire National Assembly and as well as 37 members of the Senate to succeed Gnassingbé as the country's first ceremonial president. The reforms were criticized by the opposition as an attempt for Gnassingbé to remain in power, given the fact that the president of the Council of Ministers has no term limits. They also said that Gnassingbé transferred to this role in an attempt to keep his family's dominance over the country. In June 2025, shortly after Gnassingbé became president of the Council of Ministers, mass protests were held by youth leaders against Gnassingbé, calling for his resignation.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.